MétaCan
Menu
Retour à la cohorte
Enregistrement W2125242066 · doi:10.1200/jco.2012.43.5891

Cancer Survivorship: Why Labels Matter

2012· article· en· W2125242066 sur OpenAlexaff
Kirsten Bell, Svetlana Ristovski‐Slijepcevic

Notice bibliographique

RevueJournal of Clinical Oncology · 2012
Typearticle
Langueen
DomaineMedicine
ThématiquePalliative Care and End-of-Life Issues
Établissements canadiensUniversity of British Columbia
Organismes subventionnairesnon disponible
Mots-clésCancerCancer survivorshipSurvivorship curveMedicineDiseaseMeaning (existential)ConfusionGerontologyPsychotherapistPsychologyPathologyPsychoanalysisInternal medicine

Résumé

récupéré en direct d'OpenAlex

Until relatively recently, the prevailing view was that a diagnosis of cancer was effectively a death sentence. However, the last 30 years have witnessed the transformation of cancer from a largely fatal disease to one in which a majority of those diagnosed receive treatments that result in long-term disease-free survivorship. This improvement in survival rates has been accompanied by a shift from talk of cancer victims to cancer survivors. The concept of cancer survivorship has been widely debated over the past few decades. In biomedical usage, the term survivor has a distinct clinical meaning, referring to individuals who have had a life-threatening disease but have remained disease free for a minimum of 5 years. However, in recent years, a variety of other definitions have been outlined. Proposed definitions differ primarily around the scope of populations covered; some refer only to those diagnosed with cancer, whereas others extend to family, friends, and caregivers. Complicating the picture is the distinction drawn between the terms cancer survivor and cancer survivorship. Although the former is used to encapsulate individuals throughout the cancer trajectory, the latter refers to a distinct phase in the cancer trajectory between primary treatment and cancer recurrence or end of life. Although each definition is an attempt to fully describe those who have been affected by cancer, their differences have contributed to ongoing confusion about who should be called a cancer survivor. Referring to the lack of consensus on how the cancer survivor is defined, Khan et al ask, “Does it really matter—is this debate trivial?” Continuing this discussion, we expand on the context in which the concept of the cancer survivor has developed, arguing that beneath what might seem like a trivial definitional debate lurks a more complicated concept structured by larger historical, social, cultural, and political forces. Most historical overviews of the concept of the cancer survivor generally attribute the first usage of the term to Fitzhugh Mullan, who argued against the dominant view that there are two different paths for people diagnosed with cancer: a path for those who are cured, and a separate path for those who are not. In his view, there was one path for people diagnosed with cancer: that of survival, dominated by dealing with the physical and psychological effects of diagnosis and treatment. He divided survival into three distinct seasons: acute survival, the period after diagnosis, when energies are focused on surviving treatment itself; extended survival, the period after completion of treatment, when the survivor’s energies are focused on dealing with the physical and psychological consequences of treatment; and permanent survival, the period when recurrence seems increasingly unlikely, although the survivor is continuing to deal with the long-term effects of treatment. Mullan’s dual status as a cancer survivor and a physician likely played no small role in the legitimacy accorded to the concept and the momentum his commentary generated for the nascent cancer survivor movement. The concept of the cancer survivor soon captured the imagination of those affected by and working in the field of cancer by drawing attention to the ongoing issues people with a history of cancer face after they have been successfully treated, many of which stem from the iatrogenic consequences of treatment itself. It also articulated the reality that people with a history of cancer do not just rejoin the land of the well when they are deemed cancer free. Rather, they live in the ambiguous space between the well and sick. In 1986, Mullan, along with representatives from 20 organizations, founded the National Coalition for Cancer Survivorship, a survivor-led advocacy organization seeking to change the focus from cancer victim to survivor. The National Coalition for Cancer Survivorship argued that “from the time of its discovery and for the balance of life, an individual diagnosed with cancer is a survivor.” Founded in 1996, the Office of Cancer Survivorship of the National Cancer Institute has retained the spirit of this definition while expanding it to suggest that “family members, friends, and care-givers are also impacted by the survivorship experience and are therefore included in this definition.” However, the Office of Cancer Survivorship also emphasizes the distinction between the concept of the cancer survivor and the cancer survivorship phase, choosing to focus its activities on the latter because of its relative neglect in advocacy, education, clinical practice, and research. These various definitions demonstrate that the concepts of the cancer survivor and cancer survivorship are far from neutral. They are not just attempts to describe something but to do something: to mobilize patients, oncologists, researchers, and all others affected by or invested in the experience of cancer. Although these developments are central to understanding debates about the term cancer survivor today, to fully understand the concept, we need to go back further in time, because the term survivor itself has been around for centuries—although its connotations have shifted over time. The oldest references appeared in the late 16th century and referred to a survivor in relation to the death of another/ others. For example, in 1594, Shakespeare made reference to “thy surviving husband” in his poem “The Rape of Lucrece,” reflecting its legal usage at the time, whereby the survivor of someone gained the rights/inheritance of the deceased. JOURNAL OF CLINICAL ONCOLOGY COMMENTS AND CONTROVERSIES VOLUME 31 NUMBER 4 FEBRUARY 1 2013

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,040
score de la tête « metaresearch » (Gemma)0,171
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: Sans objet
GenreSignal candidat: Commentaire · Signal consensuel: Commentaire
Score de désaccord entre enseignants0,040
Score d'incertitude au seuil0,213

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0400,171
Méta-épidémiologie (sens strict)0,0010,001
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0040,005
Études des sciences et des technologies0,0070,026
Communication savante0,0130,024
Science ouverte0,0040,007
Intégrité de la recherche0,0110,018
Charge utile insuffisante (le modèle a refusé de juger)0,0130,005

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,504
Tête enseignante GPT0,611
Écart entre enseignants0,107 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSans objet
Domainenon disponible
GenreCommentaire

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations124
Publié2012
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueJournal of Clinical OncologyMême sujetPalliative Care and End-of-Life IssuesTravaux en français237 207